APA

Konecny G. E., Finkler N., Garcia A. A., Lorusso D., Lee P. S., Rocconi R. P., Fong P. C., Squires M., Mishra K., Upalawanna A., Wang Y. & Kristeleit R. (20150831). Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. : The Lancet. Oncology.

Chicago

Konecny Gottfried E, Finkler Neil, Garcia Agustin A, Lorusso Domenica, Lee Paula S, Rocconi Rodney P, Fong Peter C, Squires Matt, Mishra Kaushal, Upalawanna Allison, Wang Yongyu and Kristeleit Rebecca. 20150831. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. : The Lancet. Oncology.

Harvard

Konecny G. E., Finkler N., Garcia A. A., Lorusso D., Lee P. S., Rocconi R. P., Fong P. C., Squires M., Mishra K., Upalawanna A., Wang Y. and Kristeleit R. (20150831). Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. : The Lancet. Oncology.

MLA

Konecny Gottfried E, Finkler Neil, Garcia Agustin A, Lorusso Domenica, Lee Paula S, Rocconi Rodney P, Fong Peter C, Squires Matt, Mishra Kaushal, Upalawanna Allison, Wang Yongyu and Kristeleit Rebecca. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. : The Lancet. Oncology. 20150831.